JSJordi Serra

Jordi Serra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jordi Serra has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Misha-Miroslav Backonja

    University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA

    2 shared publications
  • Hugh Bostock

    Sobell Department Institute of Neurology University College London Queen Square WC1N 3BG London United Kingdom

    1 shared publication
  • José Ochoa

    Oregon Nerve Center Good Samaritan Hospital and Medical Center Oregon Health Sciences University 97210 Portland Oregon

    1 shared publication
  • Mario Campero

    Departamento de Ciencias Neurolo ´gicas Universidad de Chile Santiago 10D Chile; and

    1 shared publication

Latest Publications

  • Open Access

    Two Types of C Nociceptors in Human Skin and Their Behavior in Areas of Capsaicin-Induced Secondary Hyperalgesia

    by Jordi Serra, Mario Campero, Hugh Bostock, José Ochoa

    Peripheral nociceptor sensitization is accepted as an important mechanism of cutaneous primary hyperalgesia, but secondary hyperalgesia has been attributed to central mechanisms since evidence for sensitization of primary afferents has been lacking. In this study, microneurography was used to test for changes in sensitivity of C nociceptors in the area of secondary hyperalgesia caused by intradermal injection of capsaicin in humans. Multiple C units were recruited by electrical stimulation of the skin at 0.25 Hz and were identified as discrete series of dots in raster plots of spike latencies. Nociceptors slowed progressively during repetitive stimulation at 2 Hz for 3 min. According to their response to mechanical stimulation, nociceptors could be classified as either mechano-sensitive (CM) or mechano-insensitive (CMi). These two nociceptor subtypes had different axonal properties: CMi units slowed by 2% or more when stimulated at 0.25 Hz after a 3-min pause, whereas CM units slowed by i units, after delays ranging from 0.5 to 18 min. The capsaicin injections also sensitized a majority of the CMi units, so that 11 of 17 developed immediate or delayed responsiveness to mechanical stimuli. This sensitization may contribute a peripheral C fiber component to secondary hyperalgesia.


  • Pharmacologic Management Part 1: Better-Studied Neuropathic Pain Diseases

    by Misha-Miroslav Backonja, Jordi Serra

    Neuropathic pain impacts millions of people in the United States and around the world. Patients experience one of many symptoms, such as pain, paresthesia, dysesthesia, hyperalgesia, and allodynia, for many years because of unavailable or inadequate treatment. One of the major challenges in treating patients with neuropathic pain syndromes is a lack of consensus concerning the appropriate first-line treatment options for conditions associated with neuropathic pain, including postherpetic neuralgia, diabetic peripheral neuropathy, and trigeminal neuralgia. This review summarizes the published results of randomized trials involving treatment for neuropathic pain conditions. Anticonvulsants, such as gabapentin, carbamazepine, and lamotrigine, and tricyclic antidepressants, including amitriptyline and desipramine, have demonstrated efficacy in relieving pain associated with postherpetic neuralgia, diabetic peripheral neuropathy, and trigeminal neuralgia, in several studies. However, the lack of head-to-head comparison studies of these agents limits the conclusions that can be reached. Clinicians who must make decisions regarding the care of individual patients may find some guidance from the number of randomized trials with a positive outcome for each agent. Using quality-of-life study outcomes, treatment strategies must encompass the impact of therapeutic agents on the comorbid conditions of sleep disturbance and mood and anxiety disorders associated with neuropathic pain. Looking to the future, emerging therapies, such as pregabalin and newer N-methyl-D-aspartate-receptor blockers, may provide physicians and patients with new treatment options for more effective relief of pain.


  • Open Access

    Pharmacologic Management Part 2: Lesser-Studied Neuropathic Pain Diseases

    by Misha-Miroslav Backonja, Jordi Serra

    This second part of a review of the pharmacologic management of neuropathic pain diseases describes the current treatment options for three lesser-st


  • Overview of neuropathic pain syndromes

    by Jordi Serra

    Patients with peripheral nerve injury often express a variety of positive sensory symptoms. Description of these symptoms can range from "painful" to "painless" to "painless but very unpleasant." Although it is widely accepted that both peripheral and central processes may play a role in the pathophysiology of these symptoms, peripheral mechanisms in particular are often overlooked. Sensitization of nociceptor unit receptors, spontaneous or stimuli-induced ectopic impulse generation, "multiplication" of impulses, and ephaptic transmission are pathophysiologic mechanisms resolved at the peripheral level that may explain the patient's symptomatology. It is important to reach an accurate diagnosis and to investigate the pathophysiology of every individual symptom. Only when this has been achieved is it possible to plan adequate symptom-oriented therapeutic strategies. In the future, therapy will be more symptom-oriented than illness-oriented, and treatment options will most likely be tailored to fit the specific constellation of symptoms expressed by a particular patient.